Occupationally Exposed and General Population Antibody Profiles to Influenza A Viruses Circulating in Swine as Indication of Zoonotic Risk
Population immunity gaps heighten zoonotic risk to circulating swine H1 and H3 strains.
Intranasal and intramuscular H5-Matrix-M nanoparticle vaccines protects against highly pathogenic H5N1 influenza virus in mice
Novel H5-MNP vaccine technology could potentially induce protective immunity against pandemic influenza viruses in individuals with pre-existing seasonal influenza HA immunity.
Carvacrol nanoemulsion as a novel approach to augment H9N2 influenza vaccine efficacy
These results emphasize the potential of nano-emulsion technology to strengthen immune responses in poultry and boost the efficacy of avian influenza vaccines, thereby supporting more effective control against influenza virus.
Cost-Effectiveness Analysis of the High-Dose Trivalent Influenza Vaccine in the Elderly Population in Italy
The findings suggest that the high-dose vaccine may improve health outcomes while reducing healthcare costs in people aged 65 and over in Italy.
High-Dose vs Standard-Dose Influenza Vaccines in Older Adults: A Meta-Analysis
Among adults 65 years and older, does high-dose inactivated influenza vaccine (HD-IIV) provide superior protection against hospitalization and mortality compared with the standard dose?
Influenza Vaccine and Associated Infection and Death in California, 2024 to 2025
Among adults aged 65 years and older with laboratory confirmed influenza, vaccination was associated with 29% lower likelihood of death due to influenza-related causes.
Cost-effectiveness of high-dose influenza vaccination in the Netherlands: Updated analysis incorporating new evidence
HD-IIV remains cost-effective in Dutch adults aged ≥60.
Commission launched new pilot to strengthen medical countermeasure manufacturing and health preparedness
The Rapid Agile Manufacturing Partnership for Union Protection (RAMP UP) aims to accelerate the scale-up of medical countermeasure production across the EU.
